



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/381,484	02/28/2000	DEBORAH A SCHADE	MJ-729	4022
7590 05/05/2004				
NEIL C. JONES		EXAMINER		
NELSON, MULLINS, RILEY AND SCARBOROUGH		WANG, SHENGJUN		
1330 LADY STREET		ART UNIT		
COLUMBIA, SC 29201		PAPER NUMBER		
		1617		

DATE MAILED: 05/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/381,484	Applicant(s) SCHADE ET AL.	
	Examiner Shengjun Wang	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 November 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5,14-17,21 and 22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5,14-17,21 and 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>02/07/04</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1617

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted November 17, 2003 is acknowledged.

Claim Rejections 35 U.S.C. § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1-5, 14-17 and 21-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kyle (U.S. Patent 5,374,657) in view of Crozier G.L. et al. (Monatschrift Für Kinderheilkunde, Vol. 143, No. 7, 1995, page 95-98, with English translation, IDS) and Schweikhardt et al (IDS, 02/05/2004).

3. Kyle teaches an infant formula comprising DHA and ARA in comparable amounts of DHA and ARA in human breast milk, (which are about 26 mg/kcal of ARA and 8 mg/kcal of DHA, see applicants response of 11/17/03). The ratio of ARA:DHA is about 3:1 to 2:1. See the claims and the examples in columns 13-16. Kyle also teaches that the presence of ARA and DHA in infant food is critical for a healthy growth for infants. See, particularly, column 1, lines 29-53.

4. Kyle does not teach expressly the administration of the infant formula to preterm infants, or the particular ratio of ARA: DHA, and the particular amounts of ARA: DHA herein.

5. However, Crozier et al. teaches that the presence of ARA and DHA in food is particularly important for preterm infants to proper growth and development because they are unable to

Art Unit: 1617

synthesize sufficient ARA and DHA. See, particularly, the summary. Schweikhardt et al. also teach to employ ARA and DHA enriched infant formula for feeding preterm infant, wherein the ratio of ARA and DHA is essentially the same as herein claimed. See, particularly, page 1, the third paragraph and the claims of the English translation. Schweikhardt et al. further teach an oil mixture for infant formula comprising 0.12 –1% of ARA and 0.05 –0.5% of DHA. These amounts would translate to about 5-42 mg/kcal of ARA and 1.7 to 17 mg/kcal of DHA in an infant formula (based on 100 ml of infant formula contain 3.5 g of oil mixture and 120 ml of infant formula provide 100 kcal of energy (see table 1 at pages 5-6 of the translation).

6. Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to make an infant formula with the particular amount of ARA and DHA herein and use the same for feeding preterm infant.

7. A person of ordinary skill in the art would have been motivated to make an infant formula with the particular amount of ARA and DHA herein and use the same for feeding preterm infant, because preterm infants are known to be in need of food with sufficient amount of ARA and DHA and the particular amounts of ARA and DHA herein are overlapped with the amounts range known in the art. The particular amount herein is considered obvious variation within the known range. Further, optimization of the amounts of ARA and DHA, or the formula as whole, particularly for preterm infants is considered within the skill of artisan since the criticality of ARA and DHA for preterm infant growth is known in the art. Note the claimed ratio of ARA:DHA is within the broad range claimed by Kyle. See, particularly, claim 20 in Kyle.

Response to the Arguments

Art Unit: 1617

Applicants' amendments and remarks submitted November 17, 2003 have been fully considered. The amendments and remarks are persuasive with respect to the rejections under 35 U.S.C. 102, but are not persuasive as to the rejections set forth above.

The remarks with respect of rejections under 35 U.S.C.103 is moot in view of the new ground rejection.

Regarding the establishment of unexpected results, a few notable principles are well settled. It is applicant's burden to explain any proffered data and establish how any results therein should be taken to be unexpected and significant. See MPEP 716.02 (b). The claims must be commensurate in the scope with any evidence of unexpected results. See MPEP 716.02 (d). Further, it must compare the claimed subject matter with the closest prior art in order to be effective to rebut a prima facie case of obviousness. See, MPEP 716.02 (e). The data presented in the application merely compared with those formula without ARA and DHA or with DHA only enhanced formula, no comparison with those disclosed by Kyler or Schweikhardt et al. Particularly, there is no established criticality of the particular amounts herein, which is within the broad range of Schweikhardt et al. and only about 15% higher than the disclosed examples in the prior art.

8. Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p) on February 5, 2004 prompted the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 609(B)(2)(i). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1617

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang, Ph.D. whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday-Friday from 8:30 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9302.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

SHENGJUN WANG
PRIMARY EXAMINER

Shengjun Wang

April 30, 2004